Amphastar Secures Exclusive Rights to Synthetic ACTH Analog AMP-110 in $158 Million Deal
核心洞察
Amphastar Pharmaceuticals has entered into an exclusive licensing agreement with Nanjing Hanxin Pharmaceutical for AMP-110, a fully synthetic human adrenocorticotropic hormone analog targeting inflammatory and autoimmune conditions.
The deal includes $2 million upfront, up to $89 million in milestone payments, and up to $60 million in royalties, providing Amphastar exclusive rights in the US and Canada markets.
AMP-110 is currently in early-phase clinical development with promising safety data and targets a US ACTH market exceeding $684 million annually in 2024.
Amphastar Pharmaceuticals has secured exclusive licensing rights to a fully synthetic adrenocorticotropic hormone (ACTH) analog through a comprehensive agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. (搜索) The deal, valued at up to $158 million including milestones and royalties, grants Amphastar exclusive development and commercialization rights for AMP-110 in the United States and Canada.
Strategic Expansion into Synthetic Hormones
The licensing agreement represents a significant expansion of Amphastar's proprietary peptide portfolio into the inflammatory and autoimmune disease space. AMP-110 is a fully synthetic and highly purified human ACTH analog designed to address multiple therapeutic areas with a potentially improved safety profile compared to existing porcine-derived ACTH products.
"AMP-110 represents a strategically important addition to our growing proprietary peptide portfolio," said Dr. Jack Zhang, Amphastar's President and Chief Executive Officer. "This asset aligns with our long-term vision to develop innovative proprietary products. The fully synthetic nature of AMP-110 offers a potential for a differentiated safety profile, and we believe this program positions us well in a meaningful and growing therapeutic category."
Financial Structure and Market Opportunity
Under the agreement terms, Amphastar made an initial upfront payment of $2 million to Hanxin upon signing. The deal structure includes additional payments consisting of up to $14 million in development milestone payments and up to $75 million in sales milestone payments. Amphastar will also pay royalty payments to Hanxin, capped at $7.5 million per calendar year with a maximum accumulated amount of $60 million.
The agreement also includes reciprocal licensing arrangements, with Hanxin receiving a non-exclusive license from Amphastar for certain intellectual property to develop and commercialize the compound in territories outside the United States and Canada. Hanxin will pay Amphastar royalty payments based on net sales from any patents licensed under the agreement.
Clinical Development and Market Potential
AMP-110 is currently in early-phase human clinical development, with early human studies demonstrating a promising safety profile. The compound targets a substantial market opportunity, with the U.S. ACTH market exceeding $684 million annually in 2024, according to data from manufacturers in the market.
The therapeutic applications for AMP-110 span multiple inflammatory and autoimmune conditions, including treatment of acute exacerbations of multiple sclerosis (搜索), rheumatoid arthritis (搜索), gouty arthritis (搜索), systemic lupus erythematosus (搜索), ophthalmic inflammatory conditions, and infantile spasms (搜索).
Competitive Positioning
The fully synthetic nature of AMP-110 represents a potential advancement over current porcine-derived ACTH products in the market. This synthetic approach may offer manufacturing advantages and potentially improved safety characteristics, positioning the compound as a differentiated option in the established ACTH therapeutic category.
The licensing agreement aligns with Amphastar's broader strategy of developing technically-challenging generic and proprietary injectable, inhalation, and intranasal products primarily used in hospital and urgent care clinical settings.